The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
Novo Nordisk recently announced that the FDA has approved its GLP-1 anti-obesity drug, Wegovy, in pill form. This new oral version provides a convenient alternative to injections for weight loss in adults with obesity or weight-related health issues.
Jim Cramer commented on Eli Lilly's GLP-1 pill, anticipating a revolutionary impact. He also assessed other portfolio holdings, including Taiwan Semi, Chevron, SL Green, and Microsoft, providing insights into their respective sectors.
The FDA has approved Novo Nordisk's Wegovy as an oral medication for weight loss. This provides an alternative to injections for adults with obesity or weight-related health issues. The company anticipates a US launch in January.
A leading GP has identified six holiday foods that individuals using weight-loss injections should avoid during Christmas. These foods can trigger unpleasant side effects due to the medication's impact on digestion. Adjusting your diet can help mitigate these risks.
GLP-1 drugs are effective for rapid weight loss, but can lead to skin laxity and premature aging. Vol.U.Lift cream, created by a plastic surgeon, is designed to combat these effects, offering a topical solution to keep skin firm and smooth.
ShantaQuilette Carter-Williams shares her experience with GLP-1 medication after a health ultimatum. Discover how it transformed her life, health habits, and perspective on self-care.
Ozempic, along with other weight loss medications, has demonstrated potential in mitigating health risks. However, lawsuits are emerging, alleging a connection between these drugs and vision loss. Patients are filing claims against the manufacturers.
ShantaQuilette Carter-Williams shares her experience with GLP-1 medications after facing serious health issues. Her story highlights the transformative impact on her health, lifestyle, and relationships.
The GLP-1 agonist market is undergoing significant expansion, fundamentally changing how Type 2 Diabetes and obesity are addressed globally. This drug class, initially for glycemic control, has become a key therapeutic option for weight management and cardiovascular risk reduction. The rising popularity of these drugs has sparked a pharmaceutical boom, with focus shifting to advanced agonists offering even greater metabolic advantages.
